Sept 15 (Reuters) - Immunomedics Inc :Immunomedics announces agreements to exchange approximately $80.0 mln of its 4.75 pct Convertible Senior Notes due 2020 for common stock.Immunomedics- To exchange about $80.0 mln of notes, for about 14.1 million newly issued shares of co's stock plus additional number of newly issued shares.Immunomedics- upon completion, aggregate principal amount of co's 4.75 pct Convertible Senior Notes due 2020 is to be reduced to about $20.0 mln.
Full Article

Aug 4 (Reuters) - Immunomedics Inc ::Immunomedics Inc says ‍on July 31, co and Covance Inc entered into a master services agreement - SEC filing​.Immunomedics Inc - simultaneous with execution of agreement, covance and company executed a first work order with an effective date of july 31, 2017.Immunomedics - pursuant to terms of agreement, Covance to provide clinical services for clinical study or studies to co​.Immunomedics - under work order, co engaged Covance as clinical research organization to perform services in co's phase 3 clinical trial of sacituzumab govitecan.
Full Article

July 31 (Reuters) - Immunomedics Inc :Immunomedics files for offering of 34.8 million shares of common stock by selling stockholders - sec filing.Immunomedics inc says will not receive any of proceeds from sale of common stock by the selling stockholders.
Full Article

July 31 (Reuters) - Immunomedics Inc -:Files for 34.8 million shares of co's common stock by the selling stockholders - sec filing.Immunomedics Inc says will not receive any of proceeds from sale of common stock by the selling stockholders.
Full Article

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: